Method for detecting adeno-associated virus insertion site and application thereof
By employing a two-round PCR enrichment method for insertion sites and sequencing analysis, the complexity and high cost of adeno-associated virus (AAV) insertion site detection have been addressed, achieving rapid, accurate, and low-cost detection results suitable for applications in the field of adenovirus.
Patent Information
- Application Number
- CN202411292934.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies for detecting adeno-associated virus insertion sites suffer from problems such as complex detection methods, high costs, and low efficiency, making it difficult to meet the needs of clinical applications.
A two-round PCR enrichment method for insertion sites was adopted, combined with sequencing analysis. Specific amplification primers and amplification systems were designed. Through end repair, ligation of sequencing adapters, and multiple rounds of PCR amplification, a library was constructed and sequenced for analysis, enabling rapid and accurate detection of adeno-associated virus insertion sites.
It enables rapid, accurate, and low-cost detection of adeno-associated virus insertion sites, and features simple operation, accurate detection results, good repeatability, and high sensitivity, making it suitable for applications in the field of adenovirus.
Smart Images

Figure CN118932117A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of gene analysis and detection, and relates to a method for detecting an adeno-associated virus insertion site and an application thereof. Background Art
[0002] Gene therapy is an effective means of treating genetic diseases and other malignant diseases. It has been clinically applied in the treatment of severe thalassemia and blood diseases. Gene therapy with adeno-associated virus (AAV) vectors is currently the only gene therapy that has been approved in the United States and Europe and can be performed in vivo. AAV is a small virus that infects humans and other primates. The virus is a small (20 nanometers), replication-defective, non-enveloped virus. It is not yet certain whether AAV causes disease, and the virus only causes a very mild immune response. Wild-type AAV can infect dividing and non-dividing cells and may integrate its genome into the genome of host cells. These characteristics make AAV an attractive candidate for creating viral vectors for gene therapy and creating isogenic human disease models. However, due to the characteristics of AAV's random integration into the host genome, random insertion may inactivate tumor suppressor genes or activate oncogene expression, leading to the risk of carcinogenesis. Evaluation of AAV insertion sites and related safety is a necessary work and research content.
[0003] At present, there are many methods that can be used to detect the insertion site of viral vectors. High-throughput sequencing technology: Using high-throughput sequencing technology, such as whole genome sequencing, the integration site of viral vectors can be comprehensively analyzed to ensure the accuracy of the insertion site and avoid potential non-target effects; PCR method: By designing specific primers, the insertion site of the viral vector can be PCR amplified and verified by gel electrophoresis or sequencing. Specifically, there is linear amplification PCR (LAM-PCR). LAM-PCR can be used to detect rare insertion sites in complex samples such as those from peripheral blood. However, this method needs to take into account that the cutting recognition frequency of restriction endonucleases has a certain preference, which will introduce technical errors, and the experimental cycle is very long and requires a large number of monoclonal sequencing. At present, many methods for detecting viral insertion sites are mostly improved on the basis of LAM-PCR and combined with sequencing technology, mainly using biotin to label known regions and enrich insertion sites. However, due to the low binding efficiency of biotin affinity chromatography and the high template starting amount required, it is difficult to apply to preclinical or clinical samples. In addition, biotin-labeled target regions as primers also increase the synthesis cost and working time.
[0004] In summary, the development of a rapid, simple and low-cost method for detecting adeno-associated virus insertion sites is of great significance for the application field of adenovirus. Summary of the invention
[0005] In view of the deficiencies of the prior art and actual needs, the present invention provides a method for detecting an adeno-associated virus insertion site and its application, in order to achieve rapid, accurate and low-cost detection of an adeno-associated virus insertion site.
[0006] To achieve this object, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a method for detecting an adeno-associated virus insertion site, the method comprising:
[0008] Genomic DNA extracted from cells infected with adeno-associated virus;
[0009] The genomic DNA is fragmented, and the fragmented genomic DNA is end-repaired and connected to sequencing adapters; the product after connecting to the sequencing adapter is subjected to a first round of PCR amplification, wherein the nucleic acid sequence of the upstream primer of the first round of PCR amplification includes the sequence shown in SEQ ID NO.1, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.2;
[0010] The first-round PCR amplification product is subjected to a second-round PCR amplification, wherein the nucleic acid sequence of the upstream primer of the second-round PCR amplification includes the sequence shown in SEQ ID NO.3, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.4; the second-round PCR amplification product is purified, and a third-round PCR amplification is performed using the primers of the sequencing adapter, and the third-round PCR amplification product is purified to obtain a sequencing library, and the sequencing library is sequenced, and data analysis is performed on the sequencing results to analyze the adeno-associated virus insertion site.
[0011] In the present invention, a new strategy for detecting the insertion sites of adeno-associated viruses is designed, including extracting genomic DNA from cells infected with adenovirus as a sample, enriching the insertion sites through two rounds of PCR, constructing a library and detecting the insertion sites based on sequencing analysis, and further designing amplification primers and systems. The overall strategy is coordinated and simple to operate, while ensuring good detection accuracy, sensitivity and repeatability, and can be effectively applied to the field of adenovirus.
[0012] SEQ ID NO. 1: CAAGCAGAAGACGGCATACGAGAT.
[0013] SEQ ID NO. 2: CGCAGGAACCCCTAGTGATGGAG.
[0014] SEQ ID NO. 3: CAAGCAGAAGACGGCATACGAGAT.
[0015] SEQ ID NO.4:
[0016] AATGTACAGTATTGCGTTTTGGAGTTGGCCACTCCCTCTCTGC.
[0017] Preferably, the end repair comprises adding an A base to the 3' end of the DNA fragment.
[0018] It can be understood that common sequencing technologies in the art, such as the second-generation sequencing technology, are theoretically applicable to the present invention.
[0019] Preferably, the sequencing adapter comprises a universal sequencing adapter for high-throughput sequencing.
[0020] It can be understood that the sequencing adapter and the corresponding adapter primer can be selected according to the specific sequencing platform used, such as the P5 / P7 adapter containing the UMI tag.
[0021] Preferably, the first round of PCR amplification further includes a step of purifying the product after ligation of sequencing adapters.
[0022] It is understood that the gene product purification methods commonly used in the art, such as the magnetic bead method, are applicable to the present invention.
[0023] Preferably, the reaction system of the first round of PCR includes: products after ligation of sequencing adapters, buffer (such as TE PCR buffer), Q-Solution (such as 5×Q-Solution), upstream primers, downstream primers and hot start DNA polymerase (HotStarTaq DNA Polymerase).
[0024] Preferably, the reaction system of the second round of PCR comprises: amplification products of the first round of PCR, nuclease-free water, buffer, Q-Solution, upstream primers, downstream primers and hot-start DNA polymerase.
[0025] Preferably, the fragmentation method comprises sonication.
[0026] Preferably, the length of the fragmented genomic DNA is 500 to 600 bp.
[0027] Preferably, the reaction procedures of the first round of PCR and the second round of PCR each independently include:
[0028] Pre-denaturation: 94-96°C, 10-15min;
[0029] Pre-denaturation: 97-99°C, 1-3 min;
[0030] Denaturation: 97-99°C, 10-20s, annealing: 66-70°C, 8-12min, 8-12 cycles;
[0031] Final extension: 70-74°C, 3-6 min.
[0032] Preferably, the method further comprises the step of keeping the temperature at 0-4°C.
[0033] As a preferred technical solution, the method for detecting the adeno-associated virus insertion site comprises the following steps:
[0034] (1) Genomic DNA extracted from cells infected with adeno-associated virus;
[0035] (2) subjecting the genomic DNA to ultrasonic treatment to fragment the genomic DNA, and performing end repair on the fragmented genomic DNA and connecting sequencing adapters;
[0036] (3) purifying the product after ligating the sequencing adapter, and performing a first round of PCR amplification on the purified product, wherein the nucleic acid sequence of the upstream primer in the first round of PCR amplification includes the sequence shown in SEQ ID NO.1, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.2;
[0037] (4) performing a second round of PCR amplification on the product of the first round of PCR amplification, wherein the nucleic acid sequence of the upstream primer of the second round of PCR amplification includes the sequence shown in SEQ ID NO.3, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.4;
[0038] (5) Purifying the product of the second round of PCR amplification, performing a third round of PCR amplification using the primers of the sequencing adapter, purifying the product of the third round of PCR amplification to obtain a sequencing library, sequencing the sequencing library, performing data analysis on the sequencing results, and analyzing the adeno-associated virus insertion site.
[0039] In a second aspect, the present invention provides the use of the method for detecting adeno-associated virus insertion sites described in the first aspect in the preparation of adeno-associated virus gene therapy drugs.
[0040] In a third aspect, the present invention provides a method for preparing an adeno-associated virus gene therapy drug, the method comprising:
[0041] The method for detecting adeno-associated virus insertion sites described in the first aspect is used to analyze the insertion sites of adeno-associated viruses, and the safety is evaluated and corresponding adeno-associated virus gene therapy drugs are designed based on the insertion site information.
[0042] Compared with the prior art, the present invention has at least the following beneficial effects:
[0043] The present invention designs a method for detecting adeno-associated virus insertion sites, including designing insertion site enrichment amplification primers, an amplification system, a reaction procedure, etc., which work together as a whole to achieve rapid detection of adeno-associated virus insertion sites based on second-generation sequencing technology, and has the characteristics of simple operating steps, accurate detection results, good repeatability, high sensitivity of insertion site detection, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 This is a schematic diagram of the database construction process;
[0045] Figure 2 This is a linear analysis result diagram of the detected copy number and the expected copy number. DETAILED DESCRIPTION
[0046] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and through specific implementation methods. However, the following examples are only simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.
[0047] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0048] For the detection of the insertion site of adeno-associated virus in the human genome, the adeno-associated virus genome and the exogenous genes it carries will not be integrated into the genome of the host cell, but will be expressed independently outside the host genome. The edge of the viral genome is two T-shaped inverted terminal repeat sequences (ITR). The genome carried by the lentivirus can be integrated into the host genome, allowing the host cells to stably express the exogenous genes for a long time. The edge of the viral genome is a long terminal repeat sequence (LTR). Compared with LTR, ITR has more palindromic structures and higher GC content, and ITR sequence will break during integration. Therefore, it is more challenging than lentivirus insertion site detection and adeno-associated virus insertion site detection. The main difficulties are in two aspects: 1. Adeno-associated virus insertion site detection has extremely high requirements for primer design, because there are up to 4 palindromic structures in the ITR sequence, and the palindromic structure makes the design of inappropriate primers produce a large amount of invalid data during sequencing. Secondly, ITR will break, and primer design must consider the problem of breakpoints; 2. The PCR amplification system in adeno-associated virus insertion detection has extremely high requirements. The ITR region has a lot of palindromic structures and a high GC content. Therefore, how to open the card structure and how to unzip the high GC are huge challenges in the process of PCR system optimization. The present invention designs a strategy for detecting the insertion site of adeno-associated virus on the human genome using NGS detection technology. First, the sample is library constructed, and the insertion site enrichment is amplified and enriched by two rounds of PCR reactions. The specific steps are as follows (see the library construction process). Figure 1 ):
[0049] (1) Perform end repair on the fragmented double-stranded DNA and add the "A" base to the 3' end of the DNA fragment;
[0050] (2) Connect sequencing adapters to both ends of the DNA fragment;
[0051] (3) purifying the ligation product to remove unligated adapter sequences;
[0052] (4) insertion site amplification and enrichment, first-round PCR amplification and second-round PCR amplification;
[0053] (5) PCR amplification, enrichment and purification of the product.
[0054] By designing specific amplification primers, amplification systems, etc., and working together as a whole, effective detection of the insertion sites of adeno-associated viruses in the human genome can be achieved. It has the characteristics of simple operation steps, accurate test results, good repeatability, and high sensitivity in insertion site detection.
[0055] The main reagent information in the specific embodiment of the present invention is shown in Table 1, the oligonucleotide sequence information is shown in Table 2, and the standard product information is shown in Table 3.
[0056] Table 1
[0057]
[0058] Table 2
[0059]
[0060] Table 3
[0061] Sample No. Sample Type Adeno-associated virus insertion site information Remark PC Monoclonal chr21:16406391- Positive Standard NC wild type none Negative Standard
[0062] Specifically, the positive standard refers to genomic DNA extracted from K562 cells infected with adeno-associated virus, the infected cells are edited using a specific CRISPR / Cas9 system and transduced with an adeno-associated virus vector, and the negative standard refers to genomic DNA extracted from K562 cells.
[0063] Example 1
[0064] This embodiment provides a method for detecting an adeno-associated virus insertion site.
[0065] 1. Genomic DNA Extraction
[0066] 1.1 Collect the positive standard cells and negative standard cells by centrifugation, wash twice with 1×PBS, and finally resuspend the cells with 200μL 1×PBS.
[0067] 1.2 Use Qiagen's DNA extraction kit (QIAamp DNA Mini Kit, catalog number: 51304) to extract genomic DNA from positive standard cells and negative standard cells.
[0068] 2. Quantification of standard products
[0069] The purity of DNA was tested by Thermo Fisher Scientific's "Nanodrop 8000" and the OD260 / 280 value was recorded. The concentration of DNA was tested by Thermo Fisher Scientific's "Qubit Fluorometer".
[0070] 3. Library Construction
[0071] 3.1 DNA sample shearing
[0072] Take 500 ng of positive standard and negative standard genomic DNA, use buffer (low TE buffer) to make up the total volume to 50 μL, and then use Covaris M220 ultrasonic shearing instrument to fragment the DNA into 550 bp. The specific shearing conditions are shown in Table 4.
[0073] Table 4
[0074] Target fragment length (base pairs) 550 Maximum incident power (W) 50 The percentage of action time to total time 20% Break cycle number 200 Interruption duration (seconds / s) 28 Temperature(℃) 20 Sample volume (μL) 50
[0075] 3.2 Take out the interrupted sample from the interruption tube and transfer it to the PCR tube.
[0076] 3.3 End repair
[0077] Thaw the end repair reagent (End Prep Mix 4) and add it to the sheared DNA. Mix by pipetting. The system is shown in Table 5.
[0078] Table 5
[0079] Components volume Breaking DNA 50μL End Prep Mix 4 15μL total 65μL
[0080] Use a pipette to gently pipette 10 times to mix thoroughly, and place the sample in a PCR instrument for reaction. The reaction program is shown in Table 6.
[0081] Table 6
[0082] temperature time Heat cover On, 105℃ On 20℃ 15min 65℃ 15min 4℃ Keep
[0083] 3.4 Connector connection
[0084] Prepare the following reaction mixture on ice. Note that the UMI adapter of the kit QIAseq 12-Index I is used for ligation. The ligation system is shown in Table 7.
[0085] Table 7
[0086] Components volume End Preparation products 65μL QIAseq 12-Index I 5μL Rapid Ligation buffer 2 25μL Rapid DNA ligase 5μL total 100μL
[0087] 3.5 Record the Index information of different samples and connect the product purification
[0088] 3.5.1 Equilibrate AMPure XP magnetic beads to room temperature 30 minutes in advance.
[0089] 3.5.2 Add 70 μL AMPure XP magnetic beads (0.7×) to the above sample, pipette 10 times to mix thoroughly, place on a magnetic stand for 5 minutes to allow the DNA to bind to the magnetic beads, and discard the supernatant.
[0090] 3.5.3 Add 200 μL 80% ethanol for washing, discard the supernatant and retain the magnetic beads.
[0091] 3.5.4 Add 200 μL 80% ethanol and wash again, discard the supernatant and keep the magnetic beads, and let stand at room temperature for 5 minutes until the beads are dry.
[0092] 3.5.5 Remove the sample from the magnetic rack, add 12 μL of nuclease-free water to resuspend the magnetic beads, use a pipette to gently pipette 10 times to mix thoroughly, let it stand at room temperature for 2 minutes, then transfer it to the magnetic rack and let it stand for 5 minutes. After the liquid is clear, transfer 9.5 μL of supernatant to a new PCR tube.
[0093] 3.6 First round PCR amplification of the insertion site
[0094] Take out TEPCR buffer, IL-Forward Primer, and outer primer_Outer2 from -20°C, thaw and mix by inversion, and prepare PCR reaction solution in a PCR tube as shown in Table 8.
[0095] Table 8
[0096]
[0097]
[0098] After mixing by pipetting 10 times, the sample was placed in a PCR instrument for single primer extension amplification reaction. The reaction procedure is shown in Table 9.
[0099] Table 9
[0100]
[0101] 3.7 Second round of PCR amplification of the insertion site
[0102] Take out TEPCR buffer, IL-Forward Primer, and inner primer_Inner4 from -20°C, thaw and mix by inversion, and prepare PCR reaction solution in a PCR tube (the first round PCR product needs to be mixed before adding after it is removed from the machine), as shown in Table 10.
[0103] Table 10
[0104]
[0105]
[0106] After mixing by pipetting 10 times, the sample was placed in a PCR instrument for single primer extension amplification reaction. The reaction procedure is shown in Table 11.
[0107] Table 11
[0108]
[0109] 3.8 Purification of amplified products
[0110] 3.8.1 Equilibrate AMPure XP magnetic beads to room temperature 30 minutes in advance.
[0111] 3.8.2 Add 80 μL of nuclease-free water to the above sample, vortex and oscillate to mix the magnetic beads, pipette 100 μL of the oscillated magnetic beads into the sample, pipette 10 times to mix thoroughly, place on a magnetic stand and let stand for 5 minutes to allow the DNA to bind to the magnetic beads, and discard the supernatant;
[0112] 3.8.3 Add 200 μL 80% ethanol for washing, discard the supernatant and retain the magnetic beads.
[0113] 3.8.4 Add 200 μL 80% ethanol and wash again, discard the supernatant and keep the magnetic beads, and let stand at room temperature for 5 minutes until the beads are dry;
[0114] 3.8.5 Remove the sample from the magnetic rack, add 16 μL of nuclease-free water to resuspend the magnetic beads, use a pipette to gently pipette 10 times to mix thoroughly, let it stand at room temperature for 2 minutes, then transfer it to the magnetic rack and let it stand for 5 minutes. After the liquid is clear, transfer 13.4 μL of supernatant to a new PCR tube.
[0115] 3.9 Library Amplification
[0116] Take out UPCR buffer, IL-Universal Primer, and IL-S502 index Primer from -20°C and thaw them. Prepare the PCR reaction solution in a PCR tube as shown in Table 12.
[0117] Table 12
[0118] Components volume Target DNA 13.4μL UPCR Buffer, 5× 4μL IL-Universal Primer 0.8μL IL-S502index primer 0.8μL HotStarTaq DNA Polymerase 1μL total 20μL
[0119] Place the PCR tube in a PCR instrument and perform amplification reaction according to the conditions in Table 13.
[0120] Table 13
[0121]
[0122]
[0123] 3.10 Purification of library amplification products
[0124] 3.10.1 Equilibrate AMPure XP magnetic beads to room temperature 30 minutes in advance.
[0125] 3.10.2 Add 80 μL of nuclease-free water to the above sample, vortex to mix the magnetic beads, pipette the mixed magnetic beads into the sample for 100 seconds, pipette 10 times to mix thoroughly, place on a magnetic stand and let stand for 5 minutes to allow the DNA to bind to the magnetic beads, and discard the supernatant.
[0126] 3.10.3 Add 200 μL 80% ethanol for washing, discard the supernatant and retain the magnetic beads.
[0127] 3.10.4 Add 200 μL 80% ethanol and wash again, discard the supernatant and keep the magnetic beads, and let stand at room temperature for 5 minutes until the beads are dry.
[0128] 3.10.5 Remove the sample from the magnetic rack, add 30 μL of nuclease-free water to resuspend the magnetic beads, use a pipette to gently pipette 10 times to mix thoroughly, let it stand at room temperature for 2 minutes, then transfer it to the magnetic rack and let it stand for 5 minutes. After the liquid is clear, transfer 28 μL of the supernatant to a new PCR tube.
[0129] 4. Library Quantification and Quality Control
[0130] The constructed library was quantified using the "Qubit Fluorometer" of Thermo Fisher Scientific, and the fragment size of the constructed library was detected using the "Agilent 2100 Bioanalyzer".
[0131] 5 Sequencing
[0132] The final library was sequenced in PE150 mode using Illumina NovaSeq6000 high-throughput sequencer.
[0133] 6 Data Analysis
[0134] The virus insertion site detection and analysis process was used to analyze the offline data.
[0135] 7 Experimental results
[0136] The results are shown in Table 14. The positive standard can accurately detect the insertion site and the insertion position is consistent with the designed position, while the negative standard cannot detect the insertion site.
[0137] Table 14
[0138] Sample name Chromosome number Location Chain direction Detected copy number Expected copy number Detection Positive Standard chr21 16406391 - 390600 152000 Checkout Negative Standard NA NA NA NA NA Not detected
[0139] Example 2
[0140] 2 Sensitivity analysis
[0141] 2.1 Experimental design
[0142] The negative standard was used to dilute the positive standard to three gradients of 120, 24 and 12 copies. The library was constructed with an input of 500 ng and sequenced in PE150 mode on the Novasek 6000 platform, with a sequencing data volume of 4G.
[0143] 2.2 Experimental Results
[0144] The results are shown in Table 15. The insertion sites can be detected in all the positive standards diluted in gradient, with a minimum of 12 copies of insertion being detected, and the detected copy number has a good linear relationship with the expected copy number ( Figure 2 ).
[0145] Table 15
[0146] Sample name Chromosome number Location Chain direction Detected copy number Expected copy number PC-120 chr21 16406391 - 1089 120 PC-24 chr21 16406391 - 277 24 PC-12 chr21 16406391 - 111 12
[0147] Example 3
[0148] 3 Repeatability analysis
[0149] 3.1 Experimental design
[0150] The dilution standard PC-12 used in sensitivity analysis was selected for repeatability experiment. The intra-batch repeatability was two repeated tests performed by the same experimenter in the same batch of tests. The inter-batch repeatability was performed by two different experimenters in two independent batches of tests. Sequencing was performed in PE150 mode on the Novasek 6000 platform, and the sequencing data volume was 4G.
[0151] 3.2 Experimental Results
[0152] The results are shown in Table 16. At very low insertion copy numbers, the insertion sites can be stably detected with good intra-batch and inter-batch reproducibility.
[0153] Table 16
[0154] Sample name Chromosome number Location Chain direction Detected copy number Expected copy number Remark PC-12-1 chr21 16406391 - 143 12 Repeat 1 PC-12-2 chr21 16406391 - 101 12 Repeat 2 PC-12-3 chr21 16406391 - 132 12 Repeat 3 PC-12-4 chr21 16406391 - 128 12 Repeat 4
[0155] In summary, the present invention designs a method for detecting adeno-associated virus insertion sites, including designing insertion site enrichment amplification primers, an amplification system, a reaction procedure, etc., which work together as a whole to achieve rapid detection of adeno-associated virus insertion sites based on second-generation sequencing technology, and has the characteristics of simple operating steps, accurate detection results, good repeatability, and high sensitivity of insertion site detection.
[0156] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. A method for detecting an adeno-associated virus insertion site, characterized in that: The method comprises: Genomic DNA extracted from cells infected with adeno-associated virus; Fragmenting the genomic DNA, performing end-repair on the fragmented genomic DNA, and connecting sequencing adapters; The product after connecting the sequencing adapter is subjected to the first round of PCR amplification, wherein the nucleic acid sequence of the upstream primer of the first round of PCR amplification includes the sequence shown in SEQ ID NO.1, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.2; The first round of PCR amplification products are subjected to a second round of PCR amplification, wherein the nucleic acid sequence of the upstream primer of the second round of PCR amplification includes the sequence shown in SEQ ID NO.3, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.4; The second-round PCR amplification product is purified, and the third-round PCR amplification is performed using the primers of the sequencing adapter. The third-round PCR amplification product is purified to obtain a sequencing library, and the sequencing library is sequenced. The sequencing results are analyzed for data to analyze the adeno-associated virus insertion site.
2. The method for detecting adeno-associated virus insertion sites according to claim 1, characterized in that: The end repair involves adding A bases to the 3' ends of the DNA fragments.
3. The method for detecting adeno-associated virus insertion sites according to claim 1 or 2, characterized in that: The sequencing adapter includes a universal sequencing adapter for high-throughput sequencing.
4. The method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 3, characterized in that: The first round of PCR amplification also includes a step of purifying the product after connecting the sequencing adapter.
5. The method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 4, characterized in that: The reaction system of the first round of PCR includes: a product after connecting a sequencing adapter, a buffer, a Q-Solution, an upstream primer, a downstream primer and a hot start DNA polymerase; Preferably, the reaction system of the second round of PCR comprises: amplification products of the first round of PCR, nuclease-free water, buffer, Q-Solution, upstream primers, downstream primers and hot-start DNA polymerase.
6. The method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 5, characterized in that: The fragmentation method includes sonication.
7. The method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 6, characterized in that: The reaction procedures of the first round of PCR and the second round of PCR each independently include: Pre-denaturation: 94-96°C, 10-15min; Pre-denaturation: 97-99°C, 1-3 min; Denaturation: 97-99°C, 10-20s, annealing: 66-70°C, 8-12min, 8-12 cycles; Final extension: 70-74°C, 3-6 min.
8. The method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 7, characterized in that: The method for detecting the adeno-associated virus insertion site comprises the following steps: (1) Genomic DNA extracted from cells infected with adeno-associated virus; (2) subjecting the genomic DNA to ultrasonic treatment to fragment the genomic DNA, and performing end repair on the fragmented genomic DNA and connecting sequencing adapters; (3) purifying the product after ligating the sequencing adapter, and performing a first round of PCR amplification on the purified product, wherein the nucleic acid sequence of the upstream primer in the first round of PCR amplification includes the sequence shown in SEQ ID NO.1, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.2; (4) performing a second round of PCR amplification on the product of the first round of PCR amplification, wherein the nucleic acid sequence of the upstream primer of the second round of PCR amplification includes the sequence shown in SEQ ID NO.3, and the nucleic acid sequence of the downstream primer includes the sequence shown in SEQ ID NO.4; (5) Purifying the product of the second round of PCR amplification, performing a third round of PCR amplification using the primers of the sequencing adapter, purifying the product of the third round of PCR amplification to obtain a sequencing library, sequencing the sequencing library, performing data analysis on the sequencing results, and analyzing the adeno-associated virus insertion site.
9. Use of the method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 5 in the preparation of adeno-associated virus gene therapy drugs.
10. A method for preparing an adeno-associated virus gene therapy drug, characterized in that: The method comprises: The method for detecting adeno-associated virus insertion sites according to any one of claims 1 to 8 is used to analyze the insertion sites of adeno-associated viruses, and the safety is evaluated and corresponding adeno-associated virus gene therapy drugs are designed based on the insertion site information.
Citation Information
Cited By
Method for detecting virus integration by adopting Tn5 transposase to assist database construction
CN115029483A
